熱門資訊> 正文
Adicet Bio分享了正在进行的自身免疫性疾病患者1期研究中接受ADI-001治疗的前七名患者的初步安全性和有效性数据
2025-10-07 18:51
- Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy.
- As of the August 31, 2025 data cut-off date, all seven evaluable LN and SLE patients experienced rapid and sustained reductions in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score and Physician's Global Assessment (PGA) highlighting ADI-001's potential fordurable effect on a broad range of lupus symptoms.
- As of the August 31, 2025 data cut-off date, all five LN patients experienced improved renal function, including three complete renal responses and Definition Of Remission In Systemic lupus erythematosus (DORIS) remissions, and two partial renal responses, with all responses ongoing.
- Generally well tolerated with a favorable safety profile to date, supporting the potential for outpatient administration; no Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and no Grade 2 or higher Cytokine Release Syndrome (CRS) was observed.
- All patients discontinued immunosuppressants and either discontinued or tapered corticosteroids to physiological levels.
- Clear evidence of immune reset with subsequent emergence of naïve and previously undetected B cell repertoire following single treatment.
- Recent momentum has resulted in more than 25 clinical sites open for enrollment to date.
- Adicet plans to request a meeting with the U.S. Food and Drug Administration (FDA) in 1Q/2026 to inform Phase 2 pivotal trial design with a study anticipated to commence in 2Q/2026
推薦文章
美股異動 | 鋰電池概念股集體走高，美國雅保漲超7%；特斯拉跌超2%
美股機會日報 | 英偉達股價開盤或創新高！美國批准其向阿聯酋出口芯片；美聯儲「三把手」：支持今年進一步降息
摩根大通：對衝基金對美股的持倉仍顯謹慎 投機性倉位接近長期中位數
美聯儲威廉姆斯：正在觀察勞動力市場 支持進一步降息
人工智能熱潮推動臺積電第三季度營收超預期大增
新股暗盤 | 見證歷史！金葉國際集團一度飆升超800%；摯達科技漲超222%，中籤一手賺7454港元
新股申購 | 仿製藥、創新葯雙管齊下！海西新葯今起招股，入場費4363.57港元
華盛早報 | 哈馬斯同意停火協議，特朗普本周或去中東；降息分歧加劇！多人仍保持謹慎態度；匯豐銀行建議將恆生銀行私有化
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
